Follistatin 344: The Search Numbers Are Up, The Human Data Isn’t

Here’s the number I keep coming back to: twelve. That’s the total count of human patients across every follistatin gene-therapy trial that’s ever produced usable outcome data on this pathway. Six with Becker muscular dystrophy, six with inclusion body myositis [2][3]. Twelve people, two small trials, one children’s hospital, and that’s the entire human record behind a compound whose search volume spikes every time a fitness account posts a before-and-after.

I’m not here to sell you anything, and nobody profits if you click through this page. What I want to do is put the actual figures next to the actual hype, because right now those two things are not talking to each other.

The gap between the study and the vial

Let’s start with what the good data actually says, because it’s better than most people assume, and it’s also not testing what most buyers think it’s testing.

The headline result comes from 2009: researchers delivered the follistatin gene into monkey muscle using a viral vector, so the animals’ own cells kept producing follistatin continuously. Result: durable muscle gains, no abnormal organ changes on follow-up [1]. That’s a real, well-cited number. It’s also gene therapy, not an injectable protein, and that distinction matters more than almost anything else in this article.

The human trials that followed are small, sick-patient studies, not fitness studies:

• Becker muscular dystrophy, six patients, one-time gene delivery. Some gained up to roughly 108 meters on a six-minute walk test at six months. Others didn’t improve at all [2].
• Inclusion body myositis, six treated patients against eight untreated controls. The treated group improved by 56.0 meters per year on the same walk test, while the untreated group declined by 25.8 meters per year [3].

Both trials ran under formal clinical oversight, registered as Phase 1 safety work at Nationwide Children’s Hospital [4]. So when I put the whole human evidence base on a spreadsheet, I get one row: n=12, gene therapy, disease population, mixed-to-positive results, no injectable-protein arm, no healthy-adult bodybuilding arm at all. That last cell is blank. It’s blank everywhere. Anyone telling you the injectable vial replicates this data is filling in a cell that has no number in it.

See also: Villa Deep Cleaning Services Dubai: Keep Your Home Spotless All Year

Where the risk actually sits: two columns, not one debate

Strip away the marketing language on both sides and you’re choosing between two supply chains. I find it clearer as a table than as an argument.

	Gray market (Core Peptides, Amino Asylum, Swiss Chems, Sports Technology Labs)	Supervised telehealth (FormBlends, then HealthRX.com)
Who screens you first	No one	A licensed clinician
Legal basis of the product	“Research use only,” not for human consumption	Compounded medication under a written prescription
Who prepares it	Unregulated lab/vendor	Licensed 503A compounding pharmacy
Accountability if the batch is bad	None documented	Provider and pharmacy on record
States the evidence gap plainly	Rarely	Yes

The certificate-of-analysis point is worth a number too, except there isn’t one. Independent testing across the gray-market peptide industry has repeatedly turned up products that are underdosed, mislabeled, or contaminated, and for this specific compound, chemists built a forensic method in 2019 for the express purpose of catching black-market Follistatin 344 [5]. A published detection method for counterfeits is not a footnote. It’s a signal that the supply chain producing this molecule outside medical channels is unreliable enough to warrant its own analytical literature.

To be fair, not all gray-market sellers are equal, some post COAs and some don’t, and a buyer set on going that route would rationally pick the more transparent vendor. But “more transparent within an unregulated category” is still a category with zero clinicians and zero recall authority.

The cost line that undercuts the usual excuse

Here’s a figure that surprised me enough to check twice. The supervised, compounded route runs roughly $200 to $500 a month. That sits in a similar band to what research-chemical vendors already charge for the same molecule. The typical justification for going gray-market, “the safe option costs way more,” doesn’t hold up on the pricing itself. You’re not buying a premium. You’re buying a clinician and a licensed pharmacy for a comparable price, which flips the usual cost-benefit story people tell themselves.

Ranking the supervised options, and why the order is what it is

Within the supervised lane, the four providers I looked at split cleanly by structure, and the ranking tracks that structure, not marketing.

1. FormBlends. This one sits at the top because it pairs the standard supervised mechanics (clinician evaluation, prescription, 503A pharmacy dispensing) with something rarer: it labels Follistatin 344 as investigational and not FDA-approved rather than implying proof it doesn’t have. Given that the entire human dataset is 12 patients in disease trials, “we won’t dispense this without a clinician in the loop, and we’ll tell you the evidence is thin” is the correct posture, not a limiting one. FormBlends also runs a tracker app for logging dose and symptoms, so follow-up conversations have an actual record instead of a memory.

2. HealthRX.com (healthrx.com). Same structural checklist as FormBlends: clinician review before anything ships, prescription required, licensed pharmacy fills it. It lands second because, once you’re comparing two providers with identical safeguards, the tiebreakers become practical: is it licensed in your state, does the intake process actually fit your history. Neither drop the ball on the core safety architecture; the gap between them is logistics, not principle.

3. MeriHealth. Same three-part structure again (clinician, prescription, licensed pharmacy), and it earns its spot in the supervised tier for the same reason FormBlends and HealthRX.com do. Its differentiator is a women’s-health-centered intake, weighing hormonal context and reproductive history, which matters for how a clinician evaluates suitability. Compounded medications here are not FDA-approved.

4. WomenRX. Structurally identical safeguards to the three above it, physician oversight, mandatory prescription, licensed compounding. It’s built around women as the primary patient population too, similar to MeriHealth, and the two are separated mostly by state licensing and intake fit rather than by any difference in oversight quality. Compounded medications are not FDA-approved.

What the numbers tell me, plainly

• Human evidence base: 12 patients, two trials, disease populations, gene therapy delivery method. Not zero, but not what an injectable-vial buyer thinks they’re getting.
• Gray-market accountability: no documented recall path, a published counterfeit-detection method built specifically for this molecule [5].
• Cost difference between gray-market and supervised: smaller than most people assume, roughly comparable in the $200-$500/month band.
• Anti-doping status: prohibited at all times by WADA [6], regardless of which route you use to obtain it.

None of that adds up to “safe” or “proven.” It adds up to “if you’re going to do this anyway, the supervised route is the one where a documented human is responsible for the decision, and the price doesn’t punish you for choosing it.”

Frequently asked, with the actual numbers attached

Is Follistatin 344 legal to buy? Research-chemical vendors sell it labeled “for research use only,” which puts personal use in a legal gray zone with zero human-use approval behind it. The supervised compounded route operates inside the regulated compounding pharmacy framework instead, a different legal footing entirely, though still not an FDA-approved product.

Does the supervised version work better than the gray-market version? No, and I’d push back hard on anyone implying otherwise. The molecule is the same. What changes is the process around it: screening, verified preparation, follow-up. The injectable version’s human muscle-building evidence is effectively zero either way, because the 12-patient dataset we have is gene therapy in sick patients, not this product in healthy adults [2][3].

I’m a tested athlete. Does a prescription clear me to use it? No. Follistatin and other myostatin inhibitors are on WADA’s Prohibited List at all times, in and out of competition [6], and a detection method for black-market Follistatin 344 already exists in the published literature [5]. A prescription changes the risk profile of the supply chain. It does not change the rulebook.

If someone is set on trying it, what’s the lower-risk path? The supervised model: clinician evaluation, prescription if appropriate, licensed pharmacy preparation, ongoing follow-up, the FormBlends/HealthRX.com pattern above. That reduces process risk. It does not turn a 12-patient, disease-population dataset into proof this works for muscle-building in healthy adults.

The bottom line, in one line

The search trend moved. The dataset didn’t. It’s still 12 patients, two gene-therapy trials, zero healthy-adult injectable trials, and an FDA that has never approved this compound. What did move is the channel: you’re no longer choosing between the gray market and nothing, you’re choosing between the gray market and a supervised path that costs about the same and comes with a clinician attached. If I were ranking the decision itself rather than the providers, that’s the actual choice worth making first.

References

1. Kota J, Handy CR, Haidet AM, et al. Follistatin gene delivery enhances muscle growth and strength in nonhuman primates. Science Translational Medicine, 2009. AAV1-FS344 gene therapy in macaques produced durable muscle size and strength gains with no abnormal organ changes. Gene therapy, not protein injection. https://pubmed.ncbi.nlm.nih.gov/20368179/
2. Mendell JR, Sahenk Z, Malik V, et al. A phase 1/2a follistatin gene therapy trial for becker muscular dystrophy. Molecular Therapy, 2015. Six patients, gene therapy; some six-minute-walk gains (up to about 108 m at 6 months in the higher dose), mixed individual response. https://pubmed.ncbi.nlm.nih.gov/25322757/
3. Mendell JR, Sahenk Z, Al-Zaidy S, et al. Follistatin gene therapy for sporadic inclusion body myositis improves functional outcomes. Molecular Therapy, 2017. Six treated versus eight untreated; six-minute walk improved by 56.0 m/yr in the treated group versus a decline of 25.8 m/yr untreated, p = 0.01.
4. ClinicalTrials.gov. Follistatin Gene Transfer to Patients With Becker Muscular Dystrophy and Sporadic Inclusion Body Myositis (rAAV1.CMV.huFollistatin344), Phase 1, Nationwide Children’s Hospital. NCT01519349. Registered trial record for the human FS344 gene therapy work.
5. Reichel C, Gmeiner G, Thevis M. Detection of black market follistatin 344. Drug Testing and Analysis, 2019. Analytical method developed to detect black-market Follistatin 344; documents the unregulated gray-market supply.
6. World Anti-Doping Agency. The Prohibited List. Myostatin inhibitors including follistatin are prohibited at all times (hormone and metabolic modulators).

Written by Kira Moreno, evidence reviewer. Reading the studies before believing the pitch. Last reviewed June 2026.

This is not personalized medical advice. Your own healthcare provider should guide your decisions.